Annexon Biosciences

At Annexon Biosciences, a biopharmaceutical company, the focus is on advancing a late-stage clinical platform of novel therapies for individuals suffering from classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye. The company's innovative approach targets upstream C1q to inhibit the classical complement inflammatory cascade, with therapeutic candidates aimed at providing significant benefits across various autoimmune, neurodegenerative, and ophthalmic diseases. With proof-of-concept data in conditions such as Guillain-Barré syndrome, Huntington’s disease, and geographic atrophy, Annexon Biosciences is dedicated to rigorously advancing its mid-to-late-stage clinical trials to deliver new potential treatments to patients as swiftly as possible.